Key result
mRNA COVID-19 vaccination linked to acetylcholine-confirmed vasospastic angina in a new case report.
Why the study?
Despite widespread myocarditis reports after COVID-19 mRNA vaccination, few cases of post-vaccinal vasospastic angina have been documented.
Case Report (n=1)
No
This case report highlights the possibility of vasospastic angina as a rare adverse event following COVID-19 mRNA vaccination, suggesting it should be considered in patients presenting with new-onset resting chest pain post-vaccination.
May prompt VSA consideration in post-vaccination chest pain; leaves open causality and incidence.
We report a case of vasospastic angina (VSA) following COVID-19 mRNA vaccination. Despite the widespread occurrence of myocarditis, there have been few reports of post-vaccinal VSA. A 41-year-old male patient was referred for chest pain at rest following mRNA vaccination; he had never experienced chest pain prior to vaccination. He was diagnosed by an acetylcholine (Ach) provocation test that showed multivessel vasospasm. After the initiation of treatment with a calcium channel blocker and nitrate, no further exacerbation of chest pain was observed. To our knowledge, this constitutes the first reported case of VSA proven by Ach provocation test after COVID-19 vaccination. The vaccination may increase coronary artery spasticity. VSA should be ruled out in post-vaccine new onset resting chest pain.
No takes yet. Share an insight, caveat, or question.
Awaya et al. (2022) conducted a case report in Vasospastic angina (n=1). mRNA-BNT162b2 COVID-19 vaccine was evaluated on Diagnosis of vasospastic angina. A 41-year-old male developed vasospastic angina, confirmed by an acetylcholine provocation test, one week after receiving the mRNA-BNT162b2 COVID-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: